Primary T Cell Non-Hodgkin’s Lymphoma of the Central Nervous System

1994 ◽  
Vol 91 (3) ◽  
pp. 158-163 ◽  
Author(s):  
Sadaya Matano ◽  
Shinobu Nakamura ◽  
Shigeki Ohtake ◽  
Hirokazu Okumura ◽  
Yoko Okabe ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
T Cell ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
The Central Nervous System

scholarly journals Multicentric Involvement of Non-Hodgkin's Lymphoma in the Central Nervous System and Testis-Case Report-

2004 ◽  
Vol 44 (9) ◽  
pp. 493-496
Author(s):  
Kenichiro ONO ◽  
Hirohiko ARIMOTO ◽  
Kojiro WADA ◽  
Takashi TAKAHARA ◽  
Toshiki SHIROTANI ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Case Report ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
The Central Nervous System

scholarly journals Primary testicular non-Hodgkin's lymphoma: a review article

2007 ◽  
Vol 125 (5) ◽  
pp. 286-288 ◽  
Author(s):  
Komal Bhatia ◽  
Ashok Kumar Vaid ◽  
Sachin Gupta ◽  
Dinesh Chandra Doval ◽  
Vineet Talwar
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Hodgkin’S Lymphoma ◽  
Testicular Tumor ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Stage Disease ◽  
Non Hodgkin's Lymphoma ◽  
High Incidence ◽  
The Central Nervous System

Primary testicular non-Hodgkin's lymphoma was first described as a clinical entity in 1866. It is a rare disease and accounts for 1% of all non-Hodgkin's lymphoma, 2% of all extranodal lymphomas and 5% of all testicular neoplasms. It is the most common testicular tumor in males between sixty and eighty years of age. Testicular non-Hodgkin's lymphoma is unique in its high incidence of bilateral involvement (8-38%), and it is also the most common bilateral testicular tumor. Testicular non-Hodgkin's lymphoma has a predilection for spreading to non-contiguous extranodal sites, especially the central nervous system. Advanced-stage disease is usually managed with doxorubicin-based chemotherapy. For early-stage disease, opinion is divided regarding systemic chemotherapy following orchidectomy. The high incidence of spreading, especially to the central nervous system, leads to advocacy of the use of central nervous system prophylaxis with intrathecal chemotherapy. Prospective multicenter trials incorporating a large number of patients may lead to better guidelines for optimal management of this subtype of non-Hodgkin's lymphoma.

Primary Central Nervous System Lymphoma of T-Cell Phenotype: A Rare Variant of Non-Hodgkin’s Lymphoma Treated with CNS Directed Therapy

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4965-4965
Author(s):  
Nancy D Doolittle ◽  
Edward A Neuwelt
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
T Cell ◽  
Rare Variant ◽  
Hodgkin’S Lymphoma ◽  
Central Nervous System Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Cell Phenotype ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Abstract Primary central nervous system lymphoma (PCNSL) is a non-Hodgkin’s lymphoma confined to the craniospinal axis and/or eyes, without evidence of systemic spread. Almost all PCNSL’s are classified as large B-cell lymphoma. A rare variant of PCNSL includes lymphomas of the T-cell phenotype. Until the publication of a large retrospective series of patients (pts) (n = 45) with T-cell PCNSL (Shenkier TN, et al. J Clin Oncol2005;23:2233–2239),only case reports of T-PCNSL and literature reviews were available. The large retrospective series reported that ECOG Performance Status (PS) (0 or 1 versus 2, 3 or 4) at diagnosis was significantly associated with better outcome (Log rank P <.0001), as was primary treatment with high-dose methotrexate (MTX) (yes versus no) (Log rank P = .002). Median survival in the large series was 25 months (95% CI: 11 to 38 months). We reviewed our brain tumor database for pts seen between January 1980 and July 2008. Of 159 pts diagnosed with PCNSL, 3 (2M/1F) had histopathologically confirmed large T-cell phenotype. At diagnosis, the pts’ ages were 10, 23, and 64 years; in each case ECOG PS at diagnosis was 0. Brain parenchyma disease location was periventricular (1 pt), parietal (1 pt), and corpus callosum (1 pt); one pt had both brain and ocular lymphoma. First-line treatment was IA MTX-based chemotherapy with osmotic blood-brain barrier disruption (BBBD), without brain irradiation. The dose of MTX was 2.5 grams/day for 2 consecutive days, every 4 weeks for up to one year. A comprehensive neuropsychological test battery was administered at baseline prior to MTX-based BBBD treatment. Followup neuropsychological testing was conducted within 6 months after the final BBBD treatment. All patients attained CR and are alive 15.8, 8.9 and 1.2 years after diagnosis, with excellent PS and no evidence of disease progression to date. The 3 pts showed stable or improved neuropsychological function in all cognitive domains at follow-up testing. Side effects during BBBD treatment included focal seizures (1 pt) and atrial fibrillation (1 pt). In these 3 cases of T-cell PCNSL, encouraging tumor responses and survival were seen, with stable or improved neurocognitive functioning to date, warranting further investigation of CNS directed therapy in this rare variant of non-Hodgkin’s lymphoma.

Sign in / Sign up

Export Citation Format

Share Document